A Placebo-Controlled Study of Trazodone in Bulimia Nervosa
Journal of Clinical PsychopharmacologyPublished 1 August 1989
Harrison G. Pope, Paul E. Keck, Susan L. McElroy, James I. Hudson
Citations103
SJR quartileQ2
SJR score0.72
SNIP0.80
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The drug proved significantly superior to placebo, both in measures of frequency of binge eating and vomiting and in the patients' subjective assessments of improvement.
Abstract
Forty-two women who met the new narrower criteria for bulimia nervosa of DSM-III-R completed a placebo-controlled double-blind study with trazodone. The drug proved significantly superior to placebo, both in measures of frequency of binge eating and vomiting and in the patients' subjective assessments of improvement. Trazodone produced few adverse effects.
Keywords
Psychology